Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

AI-driven innovation in life sciences: Unlocking the page – 20+ years of digital innovation at Elsevier

Posted on December 2nd, 2021 by

AI & Data

Mark Sheehan is VP Data Science on Elsevier’s Life Science team. His 20 years at the company maps closely with Elsevier’s digital journey over that time. And today, pharmaceutical companies can follow a similar journey – albeit highly accelerated – using Elsevier’s latest AI-driven R&D boosters. Mark has enjoyed many valuable experiences along the way, from the joys of cracking open a newly printed book, to enabling people to speedily crack new synthetic pathways at scale. “Yes, innovation always involves new technology. But it’s equally about human collaboration,” he says.

(more…)

AI-driven innovation in life sciences: Data as data should be

Posted on November 17th, 2021 by

AI & Data

Your AI applications are only as strong as your data. This is why Elsevier strives to make data not only align with FAIR usability principles but also be maximized for trustworthiness and relevance. In this way we can confidently offer the full potential of data science in an easy-to-use manner – from data acquisition and preparation, to AI application and interpretation.

(more…)

Big Data in Chemistry is featured in a new webinar series

Posted on November 11th, 2021 by

Chemistry

We talk a lot about how innovation is driven by technological advances such as AI and machine learning – but equally important to innovation are partnerships and collaborations. The R&D Collaboration Network, founded in 2015, brings together top-class researchers in chemical informatics and computational chemistry who need access to comprehensive, accurate, diverse and deep sources of chemical data as input to their research programs, in order to drive innovation via the development of visual and/or predictive analytics approaches.

(more…)

AI-driven innovation in Life Sciences: Data Science & AI amplifies your innovative drug R&D capabilities

Posted on November 4th, 2021 by

AI & Data

If you work in Life Sciences & Health, you’re likely aware of what Data Science and AI can bring to the table when it comes to sparking innovation. However, if you are not Big Pharma, it’s the how that slows down most LSH companies and organizations. We believe that Elsevier’s road-tested data and semantic technologies can address the challenges of Life Science data.

(more…)

Emerging trends for pancreatitis in the scientific literature: a new report

Posted on October 19th, 2021 by

Pharma R&D

Elsevier has just released the Emerging trends for pancreatitis in the scientific literature report, which identifies proteins and genes linked to pancreatitis. Elsevier’s Professional Services team prepared it pro bono for Mission: Cure, a foundation that is focused on finding a disease-modifying treatment for pancreatitis. The team hopes that all researchers working on pancreatitis, which affects millions of people worldwide in both acute and chronic forms, will find it useful.

(more…)

Finding drug information can be hard – healthcare providers need digital solutions

Posted on October 5th, 2021 by

Medical Information

The digital transformation in our world was already happening quite rapidly in recent years, but then the COVID-19 pandemic accelerated many aspects of it. Not only did schools and businesses have to learn to function online, but everything from doctor’s visits to dance parties were frequently being conducted on the internet. But even as many sectors have made the digital transition, some areas have continued to lag behind.

(more…)

  1. 1
  2. 2
  3. 3
  4. …
  5. 87

About this Blog

iStock_000019748868_Full

The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.

Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier,  its affiliates and sponsors or its parent company, Reed Elsevier.